From Daviste,
‘We have been over this already. Aclarubicin suffers the same issue that bisantrene does as a substitute for doxorubicin - no clinician will switch. Bisantrene works as well or even better than doxorubicin (according to the Phase 3 breast cancer trial) yet we can’t get any clinician interested in switching over to using it. For better or worse, any solution to the doxorubicin cardiotoxicity problem is going to require making doxorubicin safer and better, not finding a better anthracycline.’
So you need to walk before you run, get some sort of acceptance in combination, then look at the cancer figures pre and then post combination.
From Daviste, ‘We have been over this already. Aclarubicin...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |